Creative Biolabs ADC Blog

Menu

Skip to content
  • Home
  • Antibody-drug Conjugates Research
  • Antibody-drug Conjugates Manufacturing
  • News

Category Archives: Uncategorized

16Dec/20

Booming 2020 for ADC—Achieved $40 billion Trade

December 16, 2020UncategorizedADC, ADC trade, HER2, HER3, Trop-2bioadc

ADC drugs are undoubtedly the focus of many pharmaceutical companies competing for layout in 2020, reaching $40 billion deal in less than a year. AstraZeneca built a partnership with the Daiichi SankyoRead More…

20Aug/20

Medical Missile-ADC Drug-Will Take-Off

August 20, 2020News, UncategorizedADC, ADC development, ADC linkers, ADC toxinsbioadc

Recently, AstraZeneca reached a global development and commercialization agreement of up to US $6 billion with the Daiichi Sankyo Company Limited for the development and commercialization of the antibody-drug conjugate (ADC). ThisRead More…

Posts navigation

  • « Previous
  • 1
  • 2

Categories

Recent Posts

  • Targeting Drug-Resistant Breast Cancer with a Novel ADC
  • Aptamer-Drug Conjugates: The Next Frontier in Targeted Cancer Therapy Shows Encouraging Results
  • A New Hope for Cancer Therapy: How ADCs are Redefining Treatment
  • Hyaluronidase-Conjugated Liposomes May Effectively Target Pancreatic Cancer
  • Beyond the Magic Bullet: How Next-Generation Linkers are Rewriting the ADC Playbook

Archives

Contact Us

USA - UK

Copyright © Creative Biolabs ADC Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Home
  • Antibody-drug Conjugates Research
  • Antibody-drug Conjugates Manufacturing
  • News